The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1831, Issue 10, 2013, Pages 1555-1565

  Huang, Jianfeng ^a   Das, Suman Kumar ^a   Jha, Pooja ^a,b   Al Zoughbi, Wael ^a   Schauer, Silvia ^a   Claudel, Thierry ^b   Sexl, Veronika ^c   Vesely, Paul ^d   Birner Gruenberger, Ruth ^a   Kratky, Dagmar ^a   Trauner, Michael ^b   Hoefler, Gerald ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

B cell lymphoma; Cachexia; Fenofibrate; Lipid metabolism; PPAR; Tumor growth

Indexed keywords

FENOFIBRATE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BONE MARROW CELL; CANCER GROWTH; CANCER SIZE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIPID METABOLISM; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; WILD TYPE;

MUS;

EID: 84885178193     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2013.04.012     Document Type: Article

References (45)

1. E.E. Calle, C. Rodriguez, K. Walker-Thurmond, M.J. Thun, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults, N. Engl. J. Med. 348 (2003) 1625-1638. (Pubitemid 36459468)
2. S.C. Larsson, A. Wolk, Body mass index and risk of non-Hodgkin's and Hodgkin's lymphoma: a meta-analysis of prospective studies, Eur. J. Cancer 47 (2011) 2422-2430.
3. CF. Skibola, E.A. Holly, M.S. Forrest, A. Hubbard, P.M. Bracci, D.R. Skibola, C. Hegedus, M.T. Smith, Body mass index, leptin and leptin receptor polymorphisms, and non- hodgkin lymphoma, Cancer Epidemiol. Biomarkers Prev. 13 (2004) 779-786. (Pubitemid 38737867)
4. J.T. Whelan, D.L. Ludwig, F.E. Bertrand, HoxA9 induces insulin-like growth factor-1 receptor expression in B-lineage acute lymphoblastic leukemia, Leukemia 22 (2008) 1161-1169. (Pubitemid 351833783)
5. A. Taslipinar, E. Bolu, L. Kebapcilar, M. Sahin, G. Uckaya, M. Kutlu, Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin's lymphoma in a patient with pituitary acromegaly, Med. Oncol. 26 (2009) 62-66.
6. S. Muntoni, L Atzori, R Mereu, G. Satta, M.D. Macis, M. Congia, A. Tedde, A. Desogus, S. Muntoni, Serum lipoproteins and cancer, Nutr. Metab. Cardiovasc. Dis. 19 (2009) 218-225.
7. A.M. Fiorenza, A. Branchi, D. Sommariva, Serum lipoprotein profile in patients with cancer, a comparison with non-cancer subjects, Int J. Clin. Lab. Res. 30 (2000) 141-145. (Pubitemid 32151973)
8. E. Kokoglu, I. Karaarslan, H.M. Karaarslan, H. Baloglu, Alterations of serum lipids and lipoproteins in breast cancer, Cancer Lett 82 (1994) 175-178. (Pubitemid 24231982)
9. M. Kuliszkiewicz-Janus, R. Malecki, A.S. Mohamed, Lipid changes occurring in the course of hematological cancers, Cell. Mol. Biol. Lett. 13 (2008) 465-474.
10. B.M. Forman, J. Chen, R.M. Evans, Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta, Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4312-4317. (Pubitemid 27194238)
11. T.M. Willson, P.J. Brown, D.D. Sternbach, B.R. Henke, The PPARs: from orphan receptors to drug discovery, J. Med. Chem. 43 (2000) 527-550. (Pubitemid 30127149)
12. G. Chinetti, J.C. Fruchart, B. Staels, Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation, Inflamm. Res. 49 (2000) 497-505.
13. J.M. Peters, Y.M. Shah, F.J. Gonzalez, The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention, Nat. Rev. 12 (2012) 181-195.
14. A. Hoelbl, C. Schuster, B. Kovacic, B. Zhu, M. Wickre, M.A. Hoelzl, S. Fajmann, F. Grebien, W. Warsch, G. Stengl, L. Hennighausen, V. Poli, H. Beug, R. Moriggl, V. Sexl, Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia, EMBO Mol. Med. 2 (1992) 98-110.
15. D.L. Sparks, M.C. Phillips, Quantitative measurement of lipoprotein surface charge by agarose gel electrophoresis, J. Lipid Res. 33 (1992) 123-130.
16. K.P. Tamilarasan, H. Temmel, S.K. Das, W. Al Zoughbi, S. Schauer, P.W. Vesely, G. Hoefler, Skeletal muscle damage and impaired regeneration due to LPL-mediated lipotoxicity, Cell death Dis. 3 (2012) e354
17. J. Folch, M. Lees, G.H. Sloane Stanley, A simple method for the isolation and purification of total lipids from animal tissues, J. Biol. Chem. 226 (1957) 497-509.
18. I. Issemann, S. Green, Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators, Nature 347 (1990) 645-650.
19. K. Tziomalos, V.G. Athyros, Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review, Int. J. Nanomedicine 1 (2006) 129-147.
20. D. Panigrahy, A. Kaipainen, S. Huang, CE. Butterfield, CM. Barnes, M. Fannon, A.M. Laforme, D.M. Chaponis, J. Folkman, M.W. Kieran, PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 985-990. (Pubitemid 351282068)
21. Z. Zak, P. Gelebart, R. Lai, Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFalpha/NF-kappaB signaling axis, Leukemia 24 (2010) 1476-1486.
22. S.R. Pyper, N. Viswakarma, S. Yu, J.K. Reddy, PPARalpha: energy combustion, hypolipidemia, inflammation and cancer, Nucl. Recept. Signal. 8 (2010) e002.
23. L. Zhang, J. Yang, J. Qian, H. Li, J.E. Romaguera, L.W. Kwak, M. Wang, Q. Yi, Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells, Blood 120 (2012) 3783-3792.
24. M. Gupta, M.J. Maurer, L.E. Wellik, M.E. Law, J.J. Han, N. Ozsan, I.N. Micallef, A Dogan, T.E. Witzig, Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP, Blood 120 (2012) 4400-4406.
25. B. Charbonneau, M.J. Maurer, S.M. Ansell, S.L. Slager, Z.S. Fredericksen, S.C. Ziesmer, W.R. Macon, T.M. Habermann, T.E. Witzig, B.K. Link, J.R. Cerhan, A.J. Novak, Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study, Cytokine 60 (2012) 882-889.
26. S. Jeong, M. Yoon, Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice, Exp. Mol. Med. 41 (2009) 397-405.
27. A. Canbay, L. Bechmann, G. Gerken, Lipid metabolism in the liver, Z. Gastroenterol. 45 (2007) 35-41. (Pubitemid 46202719)
28. J.K. Reddy, T. Hashimoto, Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system, Annu. Rev. Nutr. 21 (2001) 193-230. (Pubitemid 32695270)
29. A.A. Alizadeh, M.B. Eisen, R.E. Davis, C. Ma, I.S. Lossos, A. Rosenwald, J.C. Boldrick, H. Sabet, T. Tran, X. Yu, J.I. Powell, L. Yang, G.E. Marti, T. Moore, J. Hudson Jr., L. Lu, D.B. Lewis, R. Tibshirani, G. Sherlock, W.C. Chan, T.C. Greiner, D.D. Weisenburger, J.O. Armitage, R. Warnke, R. Levy, W. Wilson, M.R. Grever, J.C. Byrd, D. Botstein, P.O. Brown, L.M. Staudt, Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature 403 (2000) 503-511. (Pubitemid 30082188)
30. G.Q. Daley, R.A. Van Etten, D. Baltimore, Blast crisis in a murine model of chronic myelogenous leukemia, Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 11335-11338. (Pubitemid 21916035)
31. P. Gelebart, Z. Zak, M. Anand, A. Belch, R. Lai, Blockade of fatty acid synthase triggers significant apoptosis in mantle cell lymphoma, PLoS One 7 (2012) e33738.
32. A.P. Bhatt, S.R. Jacobs, A.J. Freemerman, L. Makowski, J.C. Rathmell, D.P. Dittmer, B. Damania, Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma, Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 11818-11823.
33. C.P. Pallasch, J. Schwamb, S. Konigs, A. Schulz, S. Debey, D. Kofler, J.L. Schultze, M. Hallek, A. Ultsch, C.M. Wendtner, Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells, Leukemia 22 (2008) 585-592. (Pubitemid 351386729)
34. J. Korber, S. Pricelius, M. Heidrich, M.J. Muller, Increased lipid utilization in weight losing and weight stable cancer patients with normal body weight, Eur. J. Clin. Nutr. 53 (1999) 740-745. (Pubitemid 29424005)
35. S.K. Das, S. Eder, S. Schauer, C. Diwoky, H. Temmel, B. Guertl, G. Gorkiewicz, K.P. Tamilarasan, P. Kumari, M. Trauner, R. Zimmermann, P. Vesely, G. Haemmerle, R. Zechner, G. Hoefler, Adipose triglyceride lipase contributes to cancer-associated cachexia, Science 333 (2011) 233-238.
36. R. Silverio, A. Laviano, F. Rossi Fanelli, M. Seelaender, L-carnitine induces recovery of liver lipid metabolism in cancer cachexia, Amino Acids 42 (2012) 1783-1792.
37. R.M. Krauss, Atherogenicity of triglyceride-rich lipoproteins, Am. J. Cardiol. 81 (1998) 13B-17B. (Pubitemid 28113940)
38. G. Llaverias, C. Danilo, I. Mercier, K. Daumer, F. Capozza, T.M. Williams, F. Sotgia, M.P. Lisanti, P.G. Frank, Role of cholesterol in the development and progression of breast cancer, Am. J. Pathol. 178 (2011) 402-412.
39. M. Jakobisiak, J. Golab, Potential antitumor effects of statins (Review), Int. J. Oncol. 23 (2003) 1055-1069.
40. G. Martin, K. Schoonjans, A.M. Lefebvre, B. Staels, J. Auwerx, Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators, J. Biol. Chem. 272 (1997) 28210-28217. (Pubitemid 27517759)
41. K. Schoonjans, J. Peinado-Onsurbe, A.M. Lefebvre, R.A. Heyman, M. Briggs, S. Deeb, B. Staels, J. Auwerx, PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene, EMBO J. 15 (1996) 5336-5348. (Pubitemid 26336216)
42. J.M. Peters, N. Hennuyer, B. Staels, J.C. Fruchart, C. Fievet, F.J. Gonzalez, J. Auwerx, Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice, J. Biol. Chem. 272 (1997) 27307-27312. (Pubitemid 27452695)
43. S. Qu, D. Su, J. Altomonte, A. Kamagate, J. He, G. Perdomo, T. Tse, Y. Jiang, H.H. Dong, PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1, Am. J. Physiol. 292 (2007) E421-E434. (Pubitemid 46220566)
44. N.S. Shachter, Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism, Curr. Opin. Lipidol. 12 (2001) 297-304. (Pubitemid 32521955)
45. A. Kaipainen, M.W. Kieran, S. Huang, C. Butterfield, D. Bielenberg, G. Mostoslavsky, R. Mulligan, J. Folkman, D. Panigrahy, PPARalpha deficiency in inflammatory cells suppresses tumor growth, PLoS One 2 (2007) e260.